{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:32:22Z","timestamp":1785540742674,"version":"3.56.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n The longitudinal patterns of patient-reported outcomes and their association with mortality in routine oncology care are largely unexplored.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To characterize the longitudinal patient-reported outcomes among patients undergoing chemotherapy and evaluate their association with mortality.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This secondary analysis assessed patients in the intervention arm of a cluster randomized clinical trial conducted by the Symptom Management Implementation of Patient Reported Outcomes in Oncology (SIMPRO) consortium. Patients with gastrointestinal, gynecologic, or thoracic cancer who started a new chemotherapy regimen and completed at least 1 symptom questionnaire within 180 days at medical oncology clinics at 6 hospitals (Northeast and Southern US) were assessed from September 1, 2019, to August 31, 2023. Data analysis was performed from March to September 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Electronic health record\u2013integrated symptom questionnaires along with patient education, decision support alerts, and clinical reports to facilitate symptom management.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Outcomes were patient-reported symptoms, physical function, overall well-being, and mortality. Multivariable regression identified factors associated with mortality during the 180-day follow-up period with symptoms included as time-varying covariates.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Overall, 3735 patients (median [IQR] age, 67 [59-74] years; 2196 [59%] female) submitted 35\u202f059 symptom questionnaires; 1710 (46%) were diagnosed with gastrointestinal, 1163 (31%) with thoracic, and 852 (23%) with gynecologic cancer. On multivariable analysis, moderate (hazard ratio [HR], 2.07; 95% CI, 1.34-3.20;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) and severe (HR, 3.39; 95% CI, 2.20-5.22;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) physical function deficits were associated with a higher hazard of death. Fatigue was the most common symptom reported (29 138 [83%]) followed by pain (19 959 [57%]). The prevalence of severe symptom reports decreased from 1440 of 30 660 reported symptoms (5%) in week 1 to 40 of 3528 reported symptoms (1%) in week 26, whereas moderate symptom reports decreased from 3522 of 30 660 symptoms (11%) to 265 of 3528 (8%). Other time-varying factors associated with higher hazard of death were moderate pain (HR, 1.43; 95%, CI 1.08-1.90;\n P<\/jats:italic>\n \u2009=\u2009.01), severe pain (HR, 1.66; 94% CI, 1.21-2.26;\n P<\/jats:italic>\n \u2009=\u2009.001), moderate dyspnea (HR, 1.31; 95% CI, 1.02-1.69;\n P<\/jats:italic>\n \u2009=\u2009.04), severe dyspnea (HR, 1.62; 95% CI, 1.17-2.24;\n P<\/jats:italic>\n \u2009=\u2009.004), moderate loss in appetite (HR, 1.40; 95% CI, 1.02-1.92;\n P<\/jats:italic>\n \u2009=\u2009.04), and severe loss in appetite (HR, 2.27; 95% CI, 1.55-3.33;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This secondary analysis of a cluster randomized clinical trial of patients with cancer characterized the burden of cancer-related symptoms and described normative experiences for patients receiving chemotherapy for 3 common types of cancer and found that mortality was associated with patients\u2019 evolving health status. These findings may help inform programs to monitor and manage symptoms and to deliver targeted interventions that enhance outcomes.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03850912<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.4996","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:00:43Z","timestamp":1775487643000},"page":"e264996","source":"Crossref","is-referenced-by-count":1,"title":["Longitudinal Patterns of Symptoms in Patients Undergoing Chemotherapy"],"prefix":"10.1001","volume":"9","author":[{"given":"Roshan","family":"Paudel","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexi A.","family":"Wright","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Cronin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Uno","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Barrett","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Brooks","sequence":"additional","affiliation":[{"name":"Geisel School of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah Hazard","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Department of Surgery, West Virginia University Cancer Center, Morgantown"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra L.","family":"Wong","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don S.","family":"Dizon","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Bian","sequence":"additional","affiliation":[{"name":"Maine Health Care Center, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond U.","family":"Osarogiagbon","sequence":"additional","affiliation":[{"name":"Baptist Cancer Center, Baptist Memorial Health Care, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Schrag","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Hassett","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"issue":"23","key":"zoi260183r1","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1093\/jnci\/djp386","article-title":"Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.","volume":"101","author":"Basch","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"zoi260183r2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1001\/jamaoncol.2019.5566","article-title":"Clinician vs patient reporting of baseline and postbaseline symptoms for adverse event assessment in cancer clinical trials.","volume":"6","author":"Atkinson","year":"2020","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi260183r3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/jama.2018.18085","article-title":"Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer.","volume":"321","author":"Denis","year":"2019","journal-title":"JAMA"},{"issue":"9","key":"zoi260183r4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx029","article-title":"Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients.","volume":"109","author":"Denis","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"zoi260183r5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.24793","article-title":"Patient-reported outcome measures in cancer care: an updated systematic review and meta-analysis.","volume":"7","author":"Balitsky","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi260183r6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment.","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"issue":"31","key":"zoi260183r8","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1200\/JCO.2018.78.8620","article-title":"Feasibility of implementing the patient-reported outcomes version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048.","volume":"36","author":"Basch","year":"2018","journal-title":"J Clin Oncol"},{"key":"zoi260183r9","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1200\/CCI.20.00081","article-title":"Clinical utility and user perceptions of a digital system for electronic patient-reported symptom monitoring during routine cancer care: findings from the PRO-TECT Trial.","volume":"4","author":"Basch","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"issue":"12","key":"zoi260183r10","doi-asserted-by":"publisher","first-page":"e1918","DOI":"10.1200\/OP.22.00180","article-title":"Feasibility of large-scale implementation of an electronic patient-reported outcome remote monitoring system for patients on active treatment at a community cancer center.","volume":"18","author":"Cherny","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"9","key":"zoi260183r11","doi-asserted-by":"publisher","first-page":"602","DOI":"10.6004\/jnccn.2024.7052","article-title":"Implementation of ePROs into multidisciplinary tumor board discussions for patients with pancreatic cancer: the INSPIRE intervention.","volume":"22","author":"Henderson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"zoi260183r12","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkad073","article-title":"Rationale and design for three effectiveness-implementation trials.","volume":"7","author":"Smith","year":"2023","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"key":"zoi260183r13","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.21.00137","article-title":"eSyM: an electronic health record-integrated patient-reported outcomes-based cancer symptom management program used by six diverse health systems.","volume":"6","author":"Hassett","year":"2022","journal-title":"JCO Clin Cancer Inform"},{"issue":"9","key":"zoi260183r14","doi-asserted-by":"publisher","first-page":"e714","DOI":"10.1016\/j.clml.2021.05.002","article-title":"Trajectory of symptoms in patients undergoing autologous stem cell transplant for multiple myeloma: a population-based cohort study of patient-reported outcomes.","volume":"21","author":"Ebraheem","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"zoi260183r15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41408-021-00602-4","article-title":"Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study.","volume":"12","author":"Mian","year":"2022","journal-title":"Blood Cancer J"},{"issue":"5","key":"zoi260183r16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jpainsymman.2023.01.020","article-title":"Prevalence, severity, and co-occurrence of SPPADE symptoms in 31,866 patients with cancer.","volume":"65","author":"Kroenke","year":"2023","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"zoi260183r17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35571","article-title":"Risk of significant functional impairment across cancer diagnosis and care continuum.","volume":"131","author":"Flores","year":"2025","journal-title":"Cancer"},{"issue":"11","key":"zoi260183r18","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1001\/jamaoncol.2025.3153","article-title":"Patient-reported outcomes as prognostic indicators for overall survival in cancer: a systematic review and meta-analysis.","volume":"11","author":"Huang","year":"2025","journal-title":"JAMA Oncol"},{"issue":"9","key":"zoi260183r19","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).","volume":"106","author":"Basch","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"zoi260183r20","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/jnci\/djae049","article-title":"Effects of a change in recall period on reporting severe symptoms: an analysis of a pragmatic multisite trial.","volume":"116","author":"Paudel","year":"2024","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"zoi260183r21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1740774520975120","article-title":"Composite grading algorithm for the National Cancer Institute\u2019s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).","volume":"18","author":"Basch","year":"2021","journal-title":"Clin Trials"},{"issue":"12","key":"zoi260183r22","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1109\/TVCG.2014.2346248","article-title":"UpSet: visualization of intersecting sets.","volume":"20","author":"Lex","year":"2014","journal-title":"IEEE Trans Vis Comput Graph"},{"issue":"18","key":"zoi260183r23","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1093\/bioinformatics\/btx364","article-title":"UpSetR: an R package for the visualization of intersecting sets and their properties.","volume":"33","author":"Conway","year":"2017","journal-title":"Bioinformatics"},{"issue":"3","key":"zoi260183r24","first-page":"1","article-title":"Using time dependent covariates and time dependent coefficients in the cox model.","volume":"2","author":"Therneau","year":"2017","journal-title":"Surv Vignettes"},{"issue":"1","key":"zoi260183r26","doi-asserted-by":"publisher","first-page":"570","DOI":"10.32614\/RJ-2021-053","article-title":"Reproducible summary tables with the gtsummary package.","volume":"13","author":"Sjoberg","year":"2021","journal-title":"R J"},{"issue":"1","key":"zoi260183r27","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1186\/s13063-022-06435-1","article-title":"Implementation of patient-reported outcomes for symptom management in oncology practice through the SIMPRO research consortium: a protocol for a pragmatic type II hybrid effectiveness-implementation multi-center cluster-randomized stepped wedge trial.","volume":"23","author":"Hassett","year":"2022","journal-title":"Trials"},{"issue":"5","key":"zoi260183r28","doi-asserted-by":"publisher","first-page":"448","DOI":"10.6004\/jnccn.2008.0036","article-title":"Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy.","volume":"6","author":"Butt","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"zoi260183r29","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/leu.2013.51","article-title":"Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.","volume":"27","author":"Efficace","year":"2013","journal-title":"Leukemia"},{"issue":"8","key":"zoi260183r30","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/cncr.33327","article-title":"Do all patients with cancer experience fatigue? a longitudinal study of fatigue trajectories in women with breast cancer.","volume":"127","author":"Bower","year":"2021","journal-title":"Cancer"},{"key":"zoi260183r31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2021.09.020","article-title":"Electronic patient-reported outcomes monitoring during lung cancer chemotherapy: a nested cohort within the PRO-TECT pragmatic trial (AFT-39).","volume":"162","author":"Mody","year":"2021","journal-title":"Lung Cancer"},{"issue":"1","key":"zoi260183r32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ygyno.2020.07.029","article-title":"When will I feel normal again? trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer.","volume":"159","author":"Beesley","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"3","key":"zoi260183r33","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/cncr.33956","article-title":"Self-reported quality of life as a predictor of mortality in renal cell carcinoma.","volume":"128","author":"Alam","year":"2022","journal-title":"Cancer"},{"key":"zoi260183r34","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13806","article-title":"Patient-reported outcomes predict progression-free survival of patients with advanced breast cancer treated with abemaciclib.","author":"Badaoui","year":"2021","journal-title":"Oncologist"},{"key":"zoi260183r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.10.017","article-title":"Patient-reported outcomes as independent prognostic factors for survival in oncology: systematic review and meta-analysis.","author":"Efficace","year":"2021","journal-title":"Value Health"},{"issue":"2","key":"zoi260183r36","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1200\/OP.20.00515","article-title":"Comparing clinician-assessed and patient-reported performance status for predicting morbidity and mortality in patients with advanced cancer receiving chemotherapy.","volume":"17","author":"Wood","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"7","key":"zoi260183r38","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1200\/JCO.20.02015","article-title":"Phase III randomized controlled trial of eRAPID: eHealth intervention during chemotherapy.","volume":"39","author":"Absolom","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi260183r39","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11136-023-03505-y","article-title":"Patient adherence to patient-reported outcome measure (PROM) completion in clinical care: current understanding and future recommendations.","volume":"33","author":"Unni","year":"2024","journal-title":"Qual Life Res"},{"key":"zoi260183r7","doi-asserted-by":"crossref","DOI":"10.1200\/OP.2023.19.11_suppl.569","volume-title":"Impact of Remote Symptom Monitoring (RSM) With Electronic Patient-Reported Outcomes (ePRO) on Hospitalization, Survival, and Cost in Community Oncology Practice: The Texas Two-Step Study","author":"Patt","year":"2023"},{"key":"zoi260183r25","first-page":"523","volume-title":"R survival package","author":"Therneau","year":"2013"},{"key":"zoi260183r37","doi-asserted-by":"crossref","DOI":"10.1200\/OP.2023.19.11_suppl.351","volume-title":"Patient Engagement With a Portal-Based Symptom Management Program Across Six Health Systems","author":"Hassett","year":"2023"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2847340\/paudel_2026_oi_260183_1776883067.57092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T19:00:18Z","timestamp":1776884418000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2847340"}},"subtitle":["A Secondary Analysis of a Cluster Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.4996","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]}}}